Lungs perform gas exchange while continually encountering airborne microbes, and severe lower respiratory infections remain a major global cause of mortality. Protection in the respiratory tract is provided by epithelial cells, pneumocytes and innate immune cells, along with adaptive memory responses generated after infection or vaccination. Among adaptive effectors, tissue-resident memory T (TRM) cells are recognized as central mediators of rapid local immunity at barrier sites, including the lung.
Work in animal models has shown TRM cells can provide potent protection against reinfection and heterologous pathogens. However, mouse studies have reported a relatively rapid decline of TRM cells in the lung compared with other organs, raising questions about whether human lung TRM follow the same trajectory and whether they can provide durable protection in people.
The investigators applied a T cell receptor (TCR)–guided strategy that couples single-cell transcriptomics with paired TCR repertoire profiling to assign pathogen specificity to individual lung T cells. The dataset included more than 87,000 lung T cells sampled from 40 individuals. This multimodal approach allowed simultaneous assessment of cell transcriptional states, clonal relationships and inferred antigen specificity at single-cell resolution.
The study focused on mapping the prevalence, phenotype and clonal persistence of TRM cells specific to a broad spectrum of pathogens in the human lung. Details on sampling procedures, patient demographics, exact pathogen panels used for specificity mapping, and statistical methods are not contained in the provided excerpt and therefore are not reported here.
Across the cohort, the majority of individuals harbored lung TRM cells recognizing multiple pathogens. The combined single-cell and TCR repertoire data revealed a diverse pool of pathogen-specific TRM clones in human lungs, indicating that the respiratory tract maintains memory T cell coverage against a wide spectrum of microbial threats.
The authors emphasize that this diversity was observed at the clonal level, meaning distinct T cell clones with defined TCRs mapped to different pathogen specificities. The dataset size (more than 87,000 cells) and multi-individual sampling supported robust detection of heterogeneous, pathogen-specific TRM populations.
Contrary to the pattern described in several mouse studies, the analysis showed that a large fraction of lung TRM clones persist in the human lung for extended periods—described in the abstract as many months to years. This observation indicates that, in humans, pulmonary TRM populations can be stable over clinically relevant timeframes and may provide lasting local adaptive immunity.
The excerpt does not include detailed longitudinal sampling intervals, clonal persistence rates, or the methods used to validate persistence (for example, paired sampling from the same individuals over time), so those experimental details and supporting quantitative data are not reported here.
Mouse studies have reported relatively rapid loss of lung TRM cells compared with other tissues, prompting models in which lung-draining lymph nodes serve as reservoirs that replenish the lung or in which attrition reflects a trade-off between tissue function and immune retention. The human data presented here contrast with that paradigm: human lungs appear to retain a stable, varied pool of pathogen-specific TRM cells.
This species difference has practical implications: vaccine strategies and immunotherapies designed to elicit or boost lung TRM in humans may achieve durable enhancement of local protection, whereas extrapolations from mouse lung-TRM dynamics could underpredict longevity in people.
Because TRM cells are poised for rapid local responses, the demonstration that human lungs maintain persistent, diverse, pathogen-specific TRM suggests that targeted approaches—such as mucosal vaccination—could generate long-lived local cellular immunity against respiratory pathogens. Strengthening these resident pools could reduce severity of pulmonary infections and contribute to heterologous protection across strains or related pathogens.
Specific translational recommendations, candidate vaccine platforms, or empirical data testing vaccine-induced lung TRM durability were not included in the provided excerpt and therefore are not reported here.
The source excerpt is truncated and omits several experimental and contextual details that are important for clinical interpretation. Not reported in the provided text are: sampling methodology and inclusion criteria for the 40 individuals; demographic and clinical characteristics (age, comorbidities, prior infections or vaccinations); the full list of pathogens assessed and quantitative breakdown of pathogen-specific clone frequencies; longitudinal sampling intervals and precise evidence supporting multi-month to multi-year persistence; and statistical analyses or potential confounders.
Because these elements are not present in the supplied excerpt, they cannot be summarized or used to refine clinical recommendations here.
Using single-cell transcriptomics combined with paired TCR profiling of >87,000 lung T cells from 40 people, the authors report that human lungs contain a durable and diverse pool of pathogen-specific tissue-resident memory T (TRM) cells. A substantial fraction of TRM clones persist for many months to years, a finding that differs from reported mouse lung TRM attrition and supports the concept that boosting lung TRM could yield long-lived protection against severe respiratory infections.
For clinicians and vaccine developers, these findings highlight the importance of considering human-specific TRM biology when designing mucosal or lung-directed immunization strategies. Further details on cohort characteristics, pathogen panels, and longitudinal kinetics are required to translate these observations into clinical practice; those details were not reported in the provided source excerpt.